Site icon CLINICALNEWS.ORG

Is Nicotinamide Riboside the Future of COPD Treatment? Ep. 1221 DEC 24

Is Nicotinamide Riboside the Future of COPD Treatment? Ep. 1221 DEC 24

Is Nicotinamide Riboside the Future of COPD Treatment? Ep. 1221 DEC 24

YouTube player

In a groundbreaking study, researchers explored the potential of high-dose vitamin B3 to combat inflammation in COPD. The study involved 40 COPD patients who were given either a placebo or a substantial 2 grams of vitamin B3 daily. The results were remarkable! After just 6 weeks, the group receiving vitamin B3 experienced a 53% drop in a key inflammation marker called interleukin-8 (IL-8). Even more impressive, this effect increased to a 63% reduction after 12 weeks. This suggests that vitamin B3 could be a powerful new tool in the fight against COPD.

“Find more on the Ralph Turchiano YouTube channel: @VHFILM (Channel ID: UCSxq36i1g2yb-GdmNq77U7w)”

Disclaimer:

#NR #nicotinamideriboside #COPD #lungdisease #inflammation

Norheim, K.L., Ben Ezra, M., Heckenbach, I. et al. Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial. Nat Aging 4, 1772–1781 (2024). https://doi.org/10.1038/s43587-024-00…

Chronic obstructive pulmonary disease, COPD, vitamin B3, nicotinamide, niacin, airway inflammation, interleukin-8, IL-8, randomized controlled trial, double-blind study, lung function, FEV1, FVC, high-dose supplementation, oxidative stress, therapeutic intervention, respiratory disease, chronic bronchitis, emphysema, airway remodeling, lung health, clinical research, inflammatory biomarkers, cytokine, placebo-controlled study, GOLD stage, mucus hypersecretion

Exit mobile version